How to translate text using browser tools
28 September 2021 EFFICACY OF HUMAN RECOMBINANT GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF, FILGRASTIM; NEUPOGEN®) IN NEUTROPENIC CETACEANS
Michelle R. Davis, Judy St. Leger, Lara Croft, Stacy DiRocco, Scott Gearhart, Steven Osborn, Todd Schmitt, Hendrik Nollens
Author Affiliations +
Abstract

Neutrophils are one of the initial cell lines of protection against pathogens, and when their concentrations in the blood are low, animals are highly susceptible to infections. Neutropenia has been reported in cetaceans secondary to administration of systemic sulfa antibiotics or antifungal medications and severe, overwhelming infection. Filgrastim was administered to treat neutropenia over a 15-y period in 11 cetaceans comprising four species—beluga (Delphinapterus leucas, n = 1), bottlenose dolphin (Tursiops truncatus, n = 4), killer whale (Orcinus orca, n = 5), and short-finned pilot whale (Globicephala macrorhynchus, n = 1)] ranging in age from 1 wk to >24 y. Seven study animals received multiple doses (2–6). All animals responded to at least one dose (1–7 µg/kg) of parenteral filgrastim characterized by an increase in peripheral immature (band) neutrophils, segmented neutrophils, or both. In most cases (9/11), neutrophil counts increased within 48 h of a single dose. Duration of response varied but was at least 2 wk in eight of the 11 animals and 5–9 d in the remaining animals. No adverse reactions were observed in any cases.

Copyright 2021 by American Association of Zoo Veterinarians
Michelle R. Davis, Judy St. Leger, Lara Croft, Stacy DiRocco, Scott Gearhart, Steven Osborn, Todd Schmitt, and Hendrik Nollens "EFFICACY OF HUMAN RECOMBINANT GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF, FILGRASTIM; NEUPOGEN®) IN NEUTROPENIC CETACEANS," Journal of Zoo and Wildlife Medicine 52(3), 1042-1053, (28 September 2021). https://doi.org/10.1638/2020-0046
Accepted: 11 May 2021; Published: 28 September 2021
RIGHTS & PERMISSIONS
Get copyright permission
Back to Top